MMPOWER3 Change in Endpoints From Baseline to End of Treatment (Week 24)
SE, Primary Mitochondrial Myopathy, fatigue, Fatigue
MITOCHONDRIAL MYOPATHY
In 6-minute walk test (6MWT) (A), in Primary Mitochondrial Myopathy Symptom Assessment Total Fatigue Score (PMMSA) (B), in patient global impression (PGI) of Primary Mitochondrial Myopathy Symptoms (C), and in clinician global impression (CGI) of Primary Mitochondrial Myopathy Symptoms (D). Elamipretide-treated participants reported more total fatigue at baseline and less total fatigue at end of treatment, as assessed by the PMMSA TFS. The LS mean (SE) of change from baseline to week 24 on the PMMSA TFS was −1.13 (±0.22) for participants receiving elamipretide and −1.05 (±0.22) for participants receiving placebo, a −0.07 difference between the 2 groups (95% CI −0.69 to 0.54; Secondary endpoint results are summarized in eTable 1 (